CEROW icon

CERo Therapeutics Holdings, Inc. Warrants

0.0121 USD
+0.0002
1.68%
Updated May 21, 11:56 AM EDT
1 day
1.68%
5 days
10.00%
1 month
-28.82%
3 months
1.68%
6 months
-47.62%
Year to date
21.00%
1 year
-78.96%
5 years
-97.67%
10 years
-97.67%
 

About: CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

Employees: 8

0
Funds holding %
of 7,202 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

60% more capital invested

Capital invested by funds: $28.6K [Q4 2024] → $45.7K (+$17.1K) [Q1 2025]

0.12% more ownership

Funds ownership: 2.13% [Q4 2024] → 2.26% (+0.12%) [Q1 2025]

0% more funds holding

Funds holding: 26 [Q4 2024] → 26 (+0) [Q1 2025]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Research analyst outlook

We haven’t received any recent analyst ratings for CEROW.

Financial journalist opinion

We haven’t received any recent news articles for CEROW.

Charts implemented using Lightweight Charts™